Summary
Johnson & Johnson (JNJ) filed an 8-K on January 25, 2011, to report its fourth-quarter and full-year 2010 financial results, which concluded on January 2, 2011. The filing primarily consists of a press release and supplementary financial data detailing sales and earnings for the period. Investors should review this report to understand the company's performance trends and financial health leading into the new fiscal year. While specific figures are contained within the attached exhibits, the 8-K signals a routine update on the company's operational and financial standing. The focus for investors would be on the reported sales figures across JNJ's key segments (Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Health) and the corresponding earnings per share. These details are crucial for assessing the company's growth trajectory, profitability, and its ability to meet or exceed market expectations.
Key Highlights
- 1Johnson & Johnson announced its Q4 2010 and full-year results via an 8-K filing on January 25, 2011.
- 2The report covers the financial period ending January 2, 2011.
- 3Key information is provided through an attached press release (Exhibit 99.15).
- 4Supplementary unaudited comparative sales data and condensed consolidated statements of earnings for the fourth quarter are included (Exhibit 99.2O).
- 5Investors can use this filing to assess JNJ's recent financial performance and operational results.
- 6The filing serves as official notification of the company's financial condition and results of operations for the specified period.